Is Selling Stock Like MYnd Analytics, Inc. (MYND) After This Bearish Double Bottom Pattern Winning Strategy?

September 8, 2018 - By Jack Shaw

The chart of MYnd Analytics, Inc. (MYND) shows a double bottom with $1.83 target or 5.00 % below today’s $1.93 share price. The 7 months chart pattern indicates high risk for the $12.13M company. It was reported on Sep, 8 by Finviz.com. If the $1.83 price target is reached, the company will be worth $606,400 less. Double bottoms are rare but powerful chart patterns.

The stock decreased 14.22% or $0.32 during the last trading session, reaching $1.93. About 104,949 shares traded. MYnd Analytics, Inc. (NASDAQ:MYND) has declined 63.97% since September 8, 2017 and is downtrending. It has underperformed by 76.54% the S&P500.

More notable recent MYnd Analytics, Inc. (NASDAQ:MYND) news were published by: Nasdaq.com which released: “Publication Demonstrates the Potential Positive Economic Impact to Payors and Self-insured Employers if Doctors …” on September 06, 2018, also Nasdaq.com with their article: “MYnd Analytics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City” published on August 30, 2018, Streetinsider.com published: “MYnd Analytics Inc. (MYND) Announces Publication Highlighting Positive Economic Impact to Payors from PEER …” on September 06, 2018. More interesting news about MYnd Analytics, Inc. (NASDAQ:MYND) were released by: Seekingalpha.com and their article: “MYnd Analytics up 31% on MHSRS presentation” published on August 22, 2018 as well as Seekingalpha.com‘s news article titled: “MYnd Analytics up 11% premarket on article supporting value proposition of PEER” with publication date: September 06, 2018.

MYnd Analytics, Inc. operates as a predictive analytics company. The company has market cap of $12.13 million. The firm offers objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. It currently has negative earnings. The firm uses its proprietary neurometric platform, PEER Online, to generate Psychiatric electroencephalogram Evaluation Registry (PEER) reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.